Drug Profile

D3S 001

Alternative Names: D3S-001

Latest Information Update: 08 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator D3 Bio
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pancreatic cancer
New Molecular Entity Yes

Highest Development Phases

Phase II Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Phase I/II Solid tumours

Most Recent Events

29 Apr 2025 Efficacy data from a phase I/II trial in Solid tumours released by D3 Bio
25 Nov 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumour released by D3 Bio
23 Oct 2024 Updated pharmacodynamics data from preclinical trials in Solid tumours presented at the 36^th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com